Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-05

AUTHORS

Kim Dalziel, Ali Round, Ruth Garside, Ken Stein

ABSTRACT

Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.Design and Setting: A cost-utility (Markov) model within the setting of the UK NHS and viewed from a health system perspective was adopted. Transition probabilities and relative risks were estimated from published literature. Costs of drug treatment, outpatient care, bone marrow biopsies, radiography, blood transfusions and inpatient care were obtained from the British National Formulary and local hospital databases. Costs (£, year 2001–03 values) were discounted at 6%. Quality-of-life (QOL) data were obtained from the published literature and discounted at 1.5%. The main outcome measure was cost per QALY gained. Extensive one-way sensitivity analyses were performed along with probabilistic (stochastic) analysis.Results: The incremental cost-effectiveness ratio (ICER) of imatinib, compared with IFNα, was £26 180 per QALY gained (one-way sensitivity analyses ranged from £19 449 to £51 870) and compared with hydroxycarbamide was £86 934 per QALY (one-way sensitivity analyses ranged from £69 701 to £147 095) [£1 = $US1.691 = €1.535 as at 31 December 2002].Based on the probabilistic sensitivity analysis, 50% of the ICERs for imatinib, compared with IFNα, fell below a threshold of approximately £31 000 per QALY gained. Fifty percent of ICERs for imatinib, compared with hydroxycarbamide, fell below approximately £95 000 per QALY gained.Conclusions: This model suggests, given its underlying data and assumptions, that imatinib may be moderately cost effective when compared with IFNα but considerably less cost effective when compared with hydroxycarbamide. There are, however, many uncertainties due to the lack of long-term data. More... »

PAGES

515-526

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200523050-00010

DOI

http://dx.doi.org/10.2165/00019053-200523050-00010

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039692430

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15896102


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxyurea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Markov Chains", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dalziel", 
        "givenName": "Kim", 
        "id": "sg:person.01356216720.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356216720.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Round", 
        "givenName": "Ali", 
        "id": "sg:person.0756417250.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756417250.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garside", 
        "givenName": "Ruth", 
        "id": "sg:person.01024532450.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024532450.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England", 
          "id": "http://www.grid.ac/institutes/grid.467855.d", 
          "name": [
            "Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Ken", 
        "id": "sg:person.01054372611.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6601151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050635837", 
          "https://doi.org/10.1038/sj.bjc.6601151"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002770100336", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002464869", 
          "https://doi.org/10.1007/s002770100336"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-05", 
    "datePublishedReg": "2005-05-01", 
    "description": "Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-\u03b1 or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.Design and Setting: A cost-utility (Markov) model within the setting of the UK NHS and viewed from a health system perspective was adopted. Transition probabilities and relative risks were estimated from published literature. Costs of drug treatment, outpatient care, bone marrow biopsies, radiography, blood transfusions and inpatient care were obtained from the British National Formulary and local hospital databases. Costs (\u00a3, year 2001\u201303 values) were discounted at 6%. Quality-of-life (QOL) data were obtained from the published literature and discounted at 1.5%. The main outcome measure was cost per QALY gained. Extensive one-way sensitivity analyses were performed along with probabilistic (stochastic) analysis.Results: The incremental cost-effectiveness ratio (ICER) of imatinib, compared with IFN\u03b1, was \u00a326 180 per QALY gained (one-way sensitivity analyses ranged from \u00a319 449 to \u00a351 870) and compared with hydroxycarbamide was \u00a386 934 per QALY (one-way sensitivity analyses ranged from \u00a369 701 to \u00a3147 095) [\u00a31 = $US1.691 = \u20ac1.535 as at 31 December 2002].Based on the probabilistic sensitivity analysis, 50% of the ICERs for imatinib, compared with IFN\u03b1, fell below a threshold of approximately \u00a331 000 per QALY gained. Fifty percent of ICERs for imatinib, compared with hydroxycarbamide, fell below approximately \u00a395 000 per QALY gained.Conclusions: This model suggests, given its underlying data and assumptions, that imatinib may be moderately cost effective when compared with IFN\u03b1 but considerably less cost effective when compared with hydroxycarbamide. There are, however, many uncertainties due to the lack of long-term data.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200523050-00010", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.9713537", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "incremental cost-effectiveness ratio", 
      "first-line treatment", 
      "chronic myeloid leukemia", 
      "myeloid leukemia", 
      "bone marrow biopsy", 
      "main outcome measures", 
      "health system perspective", 
      "One-way sensitivity analyses", 
      "British National Formulary", 
      "local hospital database", 
      "cost-effectiveness ratio", 
      "cost-utility model", 
      "probabilistic sensitivity analyses", 
      "blood transfusion", 
      "marrow biopsy", 
      "outpatient care", 
      "hospital database", 
      "relative risk", 
      "inpatient care", 
      "drug treatment", 
      "outcome measures", 
      "cost utility", 
      "imatinib", 
      "hydroxycarbamide", 
      "National Formulary", 
      "QALY", 
      "IFN\u03b1", 
      "UK NHS", 
      "interferon", 
      "leukemia", 
      "long-term data", 
      "treatment", 
      "care", 
      "cost effectiveness", 
      "life data", 
      "transfusion", 
      "biopsy", 
      "setting", 
      "formulary", 
      "radiography", 
      "risk", 
      "sensitivity analysis", 
      "NHS", 
      "percent", 
      "data", 
      "literature", 
      "database", 
      "analysis", 
      "measures", 
      "systems perspective", 
      "lack", 
      "utility", 
      "less cost", 
      "threshold", 
      "quality", 
      "effectiveness", 
      "ratio", 
      "model", 
      "cost", 
      "probability", 
      "perspective", 
      "design", 
      "underlying data", 
      "transition probabilities", 
      "uncertainty", 
      "probabilistic analysis", 
      "assumption"
    ], 
    "name": "Cost effectiveness of imatinib compared with interferon-\u03b1 or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia", 
    "pagination": "515-526", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039692430"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200523050-00010"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15896102"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200523050-00010", 
      "https://app.dimensions.ai/details/publication/pub.1039692430"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200523050-00010"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523050-00010'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523050-00010'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523050-00010'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200523050-00010'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      107 URIs      97 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200523050-00010 schema:about N1bbdffb1598b4d15aacec755f395b3f3
2 N28b293292d334375bfd40afcb0ec9565
3 N2fa4226eb8d4448680abdf4aee8c604f
4 N34e405b62d6742ccb2ef4f398f0b2dec
5 N4dff491aaa29424c99a6e1b688fd7855
6 N670b80cf546949e1b5a7f9e5400a0b24
7 Na52878f1f4cc47109c619ee8d4931a4c
8 Naa7f245ca93c49249f8067792abc90d9
9 Nbab5f2ee40344cf281742a92a851cb35
10 Nd27d60608ad848b49b534b110c92a2ee
11 Nd8a5984667a144b4ae01e97ba1e094bc
12 Nef465a94847a417eaffe795a10bca2ba
13 anzsrc-for:11
14 anzsrc-for:1102
15 schema:author N7778a0a1c03947a4bf8c4431f3280fbf
16 schema:citation sg:pub.10.1007/s002770100336
17 sg:pub.10.1038/sj.bjc.6601151
18 schema:datePublished 2005-05
19 schema:datePublishedReg 2005-05-01
20 schema:description Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.Design and Setting: A cost-utility (Markov) model within the setting of the UK NHS and viewed from a health system perspective was adopted. Transition probabilities and relative risks were estimated from published literature. Costs of drug treatment, outpatient care, bone marrow biopsies, radiography, blood transfusions and inpatient care were obtained from the British National Formulary and local hospital databases. Costs (£, year 2001–03 values) were discounted at 6%. Quality-of-life (QOL) data were obtained from the published literature and discounted at 1.5%. The main outcome measure was cost per QALY gained. Extensive one-way sensitivity analyses were performed along with probabilistic (stochastic) analysis.Results: The incremental cost-effectiveness ratio (ICER) of imatinib, compared with IFNα, was £26 180 per QALY gained (one-way sensitivity analyses ranged from £19 449 to £51 870) and compared with hydroxycarbamide was £86 934 per QALY (one-way sensitivity analyses ranged from £69 701 to £147 095) [£1 = $US1.691 = €1.535 as at 31 December 2002].Based on the probabilistic sensitivity analysis, 50% of the ICERs for imatinib, compared with IFNα, fell below a threshold of approximately £31 000 per QALY gained. Fifty percent of ICERs for imatinib, compared with hydroxycarbamide, fell below approximately £95 000 per QALY gained.Conclusions: This model suggests, given its underlying data and assumptions, that imatinib may be moderately cost effective when compared with IFNα but considerably less cost effective when compared with hydroxycarbamide. There are, however, many uncertainties due to the lack of long-term data.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N4df544ba45fd4cdc8fa45f7b7cc10d10
24 Na94ebf9a376e4338a50f8f7dc7660efe
25 sg:journal.1102812
26 schema:keywords British National Formulary
27 IFNα
28 NHS
29 National Formulary
30 One-way sensitivity analyses
31 QALY
32 UK NHS
33 analysis
34 assumption
35 biopsy
36 blood transfusion
37 bone marrow biopsy
38 care
39 chronic myeloid leukemia
40 cost
41 cost effectiveness
42 cost utility
43 cost-effectiveness ratio
44 cost-utility model
45 data
46 database
47 design
48 drug treatment
49 effectiveness
50 first-line treatment
51 formulary
52 health system perspective
53 hospital database
54 hydroxycarbamide
55 imatinib
56 incremental cost-effectiveness ratio
57 inpatient care
58 interferon
59 lack
60 less cost
61 leukemia
62 life data
63 literature
64 local hospital database
65 long-term data
66 main outcome measures
67 marrow biopsy
68 measures
69 model
70 myeloid leukemia
71 outcome measures
72 outpatient care
73 percent
74 perspective
75 probabilistic analysis
76 probabilistic sensitivity analyses
77 probability
78 quality
79 radiography
80 ratio
81 relative risk
82 risk
83 sensitivity analysis
84 setting
85 systems perspective
86 threshold
87 transfusion
88 transition probabilities
89 treatment
90 uncertainty
91 underlying data
92 utility
93 schema:name Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia
94 schema:pagination 515-526
95 schema:productId N9e722d3501744941b2d4eed110fb704a
96 Ncacdaa276b804699ab1d7240195d8b9c
97 Nf32b3678cc8247abbfb84b6e5933e479
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039692430
99 https://doi.org/10.2165/00019053-200523050-00010
100 schema:sdDatePublished 2022-10-01T06:33
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher Nc5504ce8afe24a578ee34a2ebfc7320a
103 schema:url https://doi.org/10.2165/00019053-200523050-00010
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N1bbdffb1598b4d15aacec755f395b3f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Benzamides
109 rdf:type schema:DefinedTerm
110 N28b293292d334375bfd40afcb0ec9565 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Hydroxyurea
112 rdf:type schema:DefinedTerm
113 N2fa4226eb8d4448680abdf4aee8c604f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Pyrimidines
115 rdf:type schema:DefinedTerm
116 N34e405b62d6742ccb2ef4f398f0b2dec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Models, Economic
118 rdf:type schema:DefinedTerm
119 N4df544ba45fd4cdc8fa45f7b7cc10d10 schema:issueNumber 5
120 rdf:type schema:PublicationIssue
121 N4dff491aaa29424c99a6e1b688fd7855 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antineoplastic Agents
123 rdf:type schema:DefinedTerm
124 N56efe1ed408c4594b93e47123492a53b rdf:first sg:person.01054372611.40
125 rdf:rest rdf:nil
126 N670b80cf546949e1b5a7f9e5400a0b24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
128 rdf:type schema:DefinedTerm
129 N6bfb58105a50490bad4e60a2e1581603 rdf:first sg:person.01024532450.24
130 rdf:rest N56efe1ed408c4594b93e47123492a53b
131 N7778a0a1c03947a4bf8c4431f3280fbf rdf:first sg:person.01356216720.78
132 rdf:rest N7b1f17125bbc4ccc9718b3590fdfe72b
133 N7b1f17125bbc4ccc9718b3590fdfe72b rdf:first sg:person.0756417250.20
134 rdf:rest N6bfb58105a50490bad4e60a2e1581603
135 N9e722d3501744941b2d4eed110fb704a schema:name dimensions_id
136 schema:value pub.1039692430
137 rdf:type schema:PropertyValue
138 Na52878f1f4cc47109c619ee8d4931a4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Piperazines
140 rdf:type schema:DefinedTerm
141 Na94ebf9a376e4338a50f8f7dc7660efe schema:volumeNumber 23
142 rdf:type schema:PublicationVolume
143 Naa7f245ca93c49249f8067792abc90d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 Nbab5f2ee40344cf281742a92a851cb35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cost-Benefit Analysis
148 rdf:type schema:DefinedTerm
149 Nc5504ce8afe24a578ee34a2ebfc7320a schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 Ncacdaa276b804699ab1d7240195d8b9c schema:name pubmed_id
152 schema:value 15896102
153 rdf:type schema:PropertyValue
154 Nd27d60608ad848b49b534b110c92a2ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Markov Chains
156 rdf:type schema:DefinedTerm
157 Nd8a5984667a144b4ae01e97ba1e094bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Imatinib Mesylate
159 rdf:type schema:DefinedTerm
160 Nef465a94847a417eaffe795a10bca2ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Interferon-alpha
162 rdf:type schema:DefinedTerm
163 Nf32b3678cc8247abbfb84b6e5933e479 schema:name doi
164 schema:value 10.2165/00019053-200523050-00010
165 rdf:type schema:PropertyValue
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
170 schema:name Cardiorespiratory Medicine and Haematology
171 rdf:type schema:DefinedTerm
172 sg:grant.9713537 http://pending.schema.org/fundedItem sg:pub.10.2165/00019053-200523050-00010
173 rdf:type schema:MonetaryGrant
174 sg:journal.1102812 schema:issn 1170-7690
175 1179-2027
176 schema:name PharmacoEconomics
177 schema:publisher Springer Nature
178 rdf:type schema:Periodical
179 sg:person.01024532450.24 schema:affiliation grid-institutes:grid.467855.d
180 schema:familyName Garside
181 schema:givenName Ruth
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024532450.24
183 rdf:type schema:Person
184 sg:person.01054372611.40 schema:affiliation grid-institutes:grid.467855.d
185 schema:familyName Stein
186 schema:givenName Ken
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40
188 rdf:type schema:Person
189 sg:person.01356216720.78 schema:affiliation grid-institutes:grid.467855.d
190 schema:familyName Dalziel
191 schema:givenName Kim
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356216720.78
193 rdf:type schema:Person
194 sg:person.0756417250.20 schema:affiliation grid-institutes:grid.467855.d
195 schema:familyName Round
196 schema:givenName Ali
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756417250.20
198 rdf:type schema:Person
199 sg:pub.10.1007/s002770100336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002464869
200 https://doi.org/10.1007/s002770100336
201 rdf:type schema:CreativeWork
202 sg:pub.10.1038/sj.bjc.6601151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050635837
203 https://doi.org/10.1038/sj.bjc.6601151
204 rdf:type schema:CreativeWork
205 grid-institutes:grid.467855.d schema:alternateName Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England
206 schema:name Peninsula Technology Assessment Group, Peninsula Medical School, Exeter, England
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...